Profiel
Kelly O’Brien Wilson currently works at Forte Animal Health, Inc., as Director from 2020 and Biostax Corp., as Chief Operating Officer from 2022.
Ms. Wilson also formerly worked at Biostax Corp., as CTO & Director-Human Resources from 2015 to 2020, Biostax Corp., as Chief Executive & Operating Officer in 2023, and Cytocom, Inc., as Chief Technology & Information Officer from 2016 to 2020.
Ms. Wilson received her undergraduate degree and graduate degree from the University of Central Florida.
Actieve functies van Kelly Wilson
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOSTAXPAR | Operationeel Directeur | 01-08-2022 |
Forte Animal Health, Inc. | Directeur/Bestuurslid | 01-12-2020 |
Eerdere bekende functies van Kelly Wilson
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOSTAXPAR | Algemeen Directeur | 25-07-2023 |
| BIOSTAXPAR | Hoofd Techniek/Wetenschap/O&O | 01-04-2020 |
Cytocom, Inc. /Old/
Cytocom, Inc. /Old/ BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops novel small molecule immunotherapies | Hoofd Techniek/Wetenschap/O&O | 01-04-2020 |
Opleiding van Kelly Wilson
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
University of Central Florida
University of Central Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biostax Corp.
Biostax Corp. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical & biotechnology products | Health Technology |
Cytocom, Inc. /Old/
Cytocom, Inc. /Old/ BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops novel small molecule immunotherapies | Health Technology |
Forte Animal Health, Inc. | Process Industries |
















